LRRK2 and nut midline carcinoma: To address this question, we analyzed another cohort of subjects (n = 10 controls, n = 12 R1441G-LRRK2 PD, n = 9 R1441G-LRRK2 non-manifesting carriers (NMC), n = 7 G2019S-LRRK2 PD, n = 6 G2019S-LRRK2 NMC, n = 4 idiopathic PD) (Table 2).